Alivus Life Sciences Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

EBITDA margin expansionExceptional itemResults View source PDF Explain this filing

ALIVUS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-2.9%Reaction day

₹1066.00

prior close

₹1060.00

announcement price

After-mkt

timing

Nifty Microcap 250market · index membership as recorded later (tracked since Jun 2026)-0.4%-2.5% vs market

Pharmaceuticals peers, median of 160sector-0.1%-2.8% vs sector

On the reaction day the stock moved 2.5 pts less than Nifty Microcap 250 and 2.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.9

10m

+0.9

15m

+0.4

30m

+1.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-2.9-0.4-2.5-0.1-2.8

Next day

-1.2-1.7+0.5-0.9-0.3

-0.4-1.3+0.9-0.2-0.2

-0.4-0.7+0.3+0.3-0.7

-0.6+0.4-1.0+1.1-1.6

-2.5+0.5-3.0+0.2-2.7

+2.1+2.8-0.7+1.0+1.2

15d

-6.3+1.2-7.5-0.2-6.1

-1.7+5.3-7.0+1.7-3.4

+9.9+9.9+0.0+7.7+2.2

+30.9+13.1+17.7+7.6+23.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Alivus Life Sciences (formerly Glenmark Life Sciences) reported FY26 revenue of Rs 25,518 million, up 6.9% from Rs 23,869 million in FY25. Profit after tax grew 16.2% to Rs 5,645 million from Rs 4,856 million. The company recognised an exceptional item of Rs 256.57 million due to the statutory impact of new labour codes (gratuity Rs 170 million and compensated absences Rs 86.55 million). EBITDA margin expanded year-over-year. The Board recommended a final dividend of Rs 5 per share (250%). Auditors issued an unmodified opinion. Operating cash flow remained healthy at Rs 5,654 million despite increased working capital outflows (trade receivables up Rs 888 million, inventories up Rs 674 million).

Likely market impact

Solid financial performance with double-digit PAT growth and margin expansion. The exceptional charge is non-recurring and regulatory-driven. The dividend payout signals confidence. Shareholders can expect positive sentiment on the back of clean audit opinion and improving profitability.